Bextra "not approvable" for migraine
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's COX-2 inhibitor Bextra (valdecoxib) is "not approvable" for treatment of migraine as of August, Pfizer's Nov. 5 10-Q filing with the Securities & Exchange Commission states. Bextra faces another setback with the expected addition of a "black box" warning to labeling regarding skin reactions. "Revised labeling for the product…will likely include the addition of a black box," the SEC filing says. The firm's Oct. 15 "Dear Doctor" letter also includes a discussion of Bextra's cardiovascular safety profile. Data showing an apparent increased risk in CV events in two studies in high-risk surgery patients were presented at the American Heart Association meeting Nov. 9...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.